V. Nicolaescu

Novel antibody language model accelerates IgG screening and design for broad-spectrum antiviral therapy

This paper introduces an antibody language model (AbLM) to accelerate IgG screening and design for broad-spectrum antiviral therapy, achieving higher precision in predicting variant-resistant antibodies.

Superiority of intranasal over systemic administration of bioengineered soluble ACE2 for survival and brain protection against SARS-CoV-2 infection

This study compares intranasal and systemic administration of bioengineered soluble ACE2 in mice, finding intranasal delivery provides better survival and brain protection against SARS-CoV-2.

SARS-CoV-2 diverges from other betacoronaviruses in only partially activating the IRE1α/XBP1 ER stress pathway in human lung-derived cells

This study compares how SARS-CoV-2 and other betacoronaviruses activate the IRE1α/XBP1 ER stress pathway in human lung cells, finding that SARS-CoV-2 only partially activates it, potentially evading host immune detection.

Polymersomes decorated with SARS-CoV-2 spike protein receptor binding domain elicit robust humoral and cellular immunity

This study develops a subunit nanovaccine using polymersomes decorated with SARS-CoV-2 RBD, showing enhanced neutralizing antibody and T cell responses in mice.

Generation of potent cellular and humoral immunity against SARS-CoV-2 antigens via conjugation to a polymeric glyco-adjuvant

This paper demonstrates that conjugating the SARS-CoV-2 Spike protein to a polymeric glyco-adjuvant elicits strong cellular and humoral immune responses in mice.

Cannabidiol Inhibits SARS-CoV-2 Replication and Promotes the Host Innate Immune Response

This study shows that cannabidiol inhibits SARS-CoV-2 replication and enhances the host innate immune response in lung cells and human patients.

Circulating ACE2-expressing Exosomes Block SARS-CoV-2 Virus Infection as an Innate Antiviral Mechanism

The paper shows that ACE2-expressing exosomes in plasma block SARS-CoV-2 infection by competing with cellular ACE2, offering a new innate antiviral mechanism.

Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of SARS-CoV-2 in vitro

The paper screens 1,900 drugs to find inhibitors of SARS-CoV-2 replication, identifies masitinib as a 3CLpro inhibitor effective in vitro, and shows its broad anti-viral activity.